Dolutegravir + Lamivudine

Dolutegravir + Lamivudine

Form: Tablet

Strength: 50 mg / 300 mg

Reference Brands: Dovato(EU & US)

Category: Anti Viral

Dolutegravir + Lamivudine is a fixed-dose combination antiretroviral medication used to treat HIV-1 infection in adults and adolescents. This two-drug regimen combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), to effectively suppress viral replication. Marketed under the brand name Dovato, it offers once-daily oral dosing with a simplified regimen, reducing pill burden. Approved by the US FDA and EMA, this dual therapy is recommended for treatment-naïve patients with no resistance to either drug. Dolutegravir + Lamivudine is known for its high efficacy, tolerability, and minimal side effects, supporting long-term HIV manageme

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.